Risk of osteoporosis and fracture incidence in patients on antipsychotic medication

Bibliography

• Hugenholtz GW, Heerdink ER, van Staa TP, Risk of hip/femur fractures in patients using antipsychotics. Bone 2005;37(6):864-70
   PubMed Web of Science ®Google Scholar
• Schlosser R, Grunder G, Anghelescu I, Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002;46(1):33-40
   PubMed Web of Science ®Google Scholar
• Neutel CI, Perry S, Maxwell S, Medication use and risk of falls. Pharmacoepidemiol Drug Saf 2002;11(2):97-104
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Gilmore JA, Liu H, Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28(Suppl 2):55-68
   PubMedGoogle Scholar
• Howard L, Kirkwood G, Leese M, Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007;190:129-34
   PubMed Web of Science ®Google Scholar
• Rey-Sanchez P, Lavado-Garcia JM, Canal-Macias ML, Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol 2009;24(1):49-54
   PubMed Web of Science ®Google Scholar
• Charoenphandhu N, Teerapornpuntakit J, Methawasin M, Prolactin decreases expression of Runx2, osteoprotegerin, and RANKL in primary osteoblasts derived from tibiae of adult female rats. Can J Physiol Pharmacol 2008;86(5):240-8
   PubMed Web of Science ®Google Scholar
• Murphy BP, Chung YC, Park TW, Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006;88(1-3):5-25
   PubMed Web of Science ®Google Scholar
• Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22(3):787-97
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989;99(Suppl):S18-27
   PubMedGoogle Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001;158(3):360-9
   PubMed Web of Science ®Google Scholar
• Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 2002;14(3):163-73
   PubMedGoogle Scholar
• Kane JM, Freeman HL. Towards more effective antipsychotic treatment. Br J Psychiatry Suppl 1994;(25):22-31
   PubMedGoogle Scholar
• Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996;124(1-2):2-34
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C, Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-9
   PubMed Web of Science ®Google Scholar
• Shapiro DA, Renock S, Arrington E, Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28(8): 1400-11
   PubMed Web of Science ®Google Scholar
• Kleinberg DL, Davis JM, de Coster R, Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19(1):57-61
   PubMed Web of Science ®Google Scholar
• Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291-314
   PubMed Web of Science ®Google Scholar
• Bole-Feysot C, Goffin V, Edery M, Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19(3):225-68
   PubMed Web of Science ®Google Scholar
• Jaber M, Robinson SW, Missale C, Dopamine receptors and brain function. Neuropharmacology 1996;35(11):1503-19
   PubMed Web of Science ®Google Scholar
• Muller EE, Locatelli V, Cella S, Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs 1983;25(4):399-432
   PubMed Web of Science ®Google Scholar
• Cowen PJ, Anderson IM, Gartside SE. Endocrinological responses to 5-HT. Ann N Y Acad Sci 1990;600:250-7; discussion 257-9
   PubMed Web of Science ®Google Scholar
• Van de Kar LD, Javed A, Zhang Y, 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 2001;21(10):3572-9
   PubMed Web of Science ®Google Scholar
• Meaney AM, O'Keane V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci 2002;71(9):979-92
   PubMed Web of Science ®Google Scholar
• Bressan RA, Erlandsson K, Spencer EP, Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl) 2004;175(3):367-73
   PubMed Web of Science ®Google Scholar
• Dickson RA, Dalby JT, Williams R, Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995;152(7):1102-3
   PubMed Web of Science ®Google Scholar
• Breier AF, Malhotra AK, Su TP, Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999;156(2):294-8
   PubMed Web of Science ®Google Scholar
• Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci 2001;251(3):141-6
   PubMed Web of Science ®Google Scholar
• Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999.;35(Suppl):S67-73
   PubMedGoogle Scholar
• Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199-204
   PubMed Web of Science ®Google Scholar
• Kapur S, Langlois X, Vinken P, The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002;302(3):1129-34
   PubMed Web of Science ®Google Scholar
• Protais P, Hermier C, Costentin J. The discriminant dopamine antagonist property of benzamides is observed at various times after their systemic or intracerebroventricular administration. Neuropharmacology 1985;24(9):861-7
   PubMed Web of Science ®Google Scholar
• Rao ML, Gross G, Strebel B, Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry 1994;35(3):151-63
   PubMed Web of Science ®Google Scholar
• Mihara K, Suzuki A, Kondo T, Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 2001;105(3):271-4
   PubMed Web of Science ®Google Scholar
• Young RM, Lawford BR, Barnes M, Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 2004;185:147-51
   PubMed Web of Science ®Google Scholar
• Nordstrom AL, Farde L, Wiesel FA, Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33(4):227-35
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57(6):553-9
   PubMed Web of Science ®Google Scholar
• Poole KE, Compston JE. Osteoporosis and its management. BMJ 2006;333(7581):1251-6
   PubMed Web of Science ®Google Scholar
• Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38(2 Suppl 1):S4-9
   PubMed Web of Science ®Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359(9319):1761-7
   PubMed Web of Science ®Google Scholar
• Becker D, Liver O, Mester R, Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003;64(7):761-6
   PubMed Web of Science ®Google Scholar
• Biller BM, Baum HB, Rosenthal DI, Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992;75(3):692-7
   PubMed Web of Science ®Google Scholar
• Meaney AM, Smith S, Howes OD, Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;184:503-8
   PubMed Web of Science ®Google Scholar
• Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003;28(Suppl 2):97-108
   PubMedGoogle Scholar
• Kishimoto T, Watanabe K, Shimada N, Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry 2008;69(3):385-91
   PubMed Web of Science ®Google Scholar
• Knegtering H, van der Moolen AE, Castelein S, What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003;28(Suppl 2):109-23
   PubMedGoogle Scholar
• O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008;22(Suppl 2):70-5
   PubMedGoogle Scholar
• Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986;314(26):1676-86
   PubMed Web of Science ®Google Scholar
• Bataille-Simoneau N, Gerland K, Chappard D, Expression of prolactin receptors in human osteosarcoma cells. Biochem Biophys Res Commun 1996;229(1):323-8
   PubMed Web of Science ®Google Scholar
• Seriwatanachai D, Krishnamra N, van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. J Cell Biochem 2009;107(4):677-85
   PubMed Web of Science ®Google Scholar
• Nixon MF, Ibrahim T, Johari Y, Managing osteoporosis in patients with fragility fractures: did the British Orthopaedic Association guidelines have any impact? Ann R Coll Surg Engl 2007;89(5):504-9
   PubMed Web of Science ®Google Scholar
• Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 2007;21(7):768-73
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976;33(3):279-86
   PubMed Web of Science ®Google Scholar
• Kuruvilla A, Peedicayil J, Srikrishna G, A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992;19(9):603-6
   PubMed Web of Science ®Google Scholar
• Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992;11(10):851-6
   PubMedGoogle Scholar
• Zelaschi NM, Delucchi GA, Rodriguez JL. High plasma prolactin levels after long-term neuroleptic treatment. Biol Psychiatry 1996;39(10):900-1
   PubMed Web of Science ®Google Scholar
• Smith S, Wheeler MJ, Murray R, The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002;22(2):109-14
   PubMed Web of Science ®Google Scholar
• Hummer M, Malik P, Gasser RW, Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005;162(1):162-7
   PubMed Web of Science ®Google Scholar
• Johnson GF, Hunt GE. The effect of thioridazine on prolactin levels in acutely schizophrenic patients: challenge-dose and steady-state levels. Aust N Z J Psychiatry 1980;14(2):127-31
   PubMed Web of Science ®Google Scholar
• Chouinard G, Annable L, Jones BD, Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system. Acta Psychiatr Scand 1981;64(5):353-62
   PubMed Web of Science ®Google Scholar
• Turkington RW. Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch Intern Med 1972;130(3):349-54
   PubMed Web of Science ®Google Scholar
• Wistedt B, Wiles D, Kolakowska T. Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 1981;1(8230):1163
   PubMed Web of Science ®Google Scholar
• Turrone P, Kapur S, Seeman MV, Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159(1):133-5
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156(2):286-93
   PubMed Web of Science ®Google Scholar
• Brunelleschi S, Zeppegno P, Risso F, Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients. Pharmacol Res 2003;48(4):405-9
   PubMed Web of Science ®Google Scholar
• David SR, Taylor C, Kinon BJ, The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22(9):1085-96
   PubMed Web of Science ®Google Scholar
• Kaneda Y, Ohmori T. Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation. Int J Neuropsychopharmacol 2003;6(3):247-52
   PubMed Web of Science ®Google Scholar
• Knegtering R, Baselmans P, Castelein S, Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005;162(5):1010-12
   PubMed Web of Science ®Google Scholar
• Heykants J, Huang ML, Mannens G, The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55(Suppl):13-17
   PubMedGoogle Scholar
• Zhang XY, Zhou DF, Yuan CL, Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Res 2002;109(3):297-302
   PubMed Web of Science ®Google Scholar
• Eberhard J, Lindstrom E, Holstad M, Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand 2007;115(4):268-76
   PubMed Web of Science ®Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151(6):825-35
   PubMed Web of Science ®Google Scholar
• Schooler N, Rabinowitz J, Davidson M, Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162(5):947-53
   PubMed Web of Science ®Google Scholar
• Claus A, Bollen J, De Cuyper H, Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85(4):295-305
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Cao LY, Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. Psychopharmacology (Berl) 2005;178(1):35-40
   PubMed Web of Science ®Google Scholar
• Konarzewska B, Wolczynski S, Szulc A, Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2009;34(1):129-39
   PubMed Web of Science ®Google Scholar
• Potkin SG, Gharabawi GM, Greenspan AJ, A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006;85(1-3):254-65
   PubMed Web of Science ®Google Scholar
• Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23(11):1839-54
   PubMed Web of Science ®Google Scholar
• Fric M, Laux G. [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine]. Psychiatr Prax 2003;30(Suppl 2):97-101
   PubMedGoogle Scholar
• Paparrigopoulos T, Liappas J, Tzavellas E, Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(1):92-6
   PubMed Web of Science ®Google Scholar
• Kopecek M, Bares M, Svarc J, Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett 2004;25(6):419-22
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Calligaro DO, Falcone JF, Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14(2):87-96
   PubMed Web of Science ®Google Scholar
• Beasley CM, Hamilton SH Jr, Crawford AM, Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7(2):125-37
   PubMed Web of Science ®Google Scholar
• Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26(1):41-54
   PubMed Web of Science ®Google Scholar
• Fulton B, Goa KL. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997;53(2):281-98
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G, 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155(7):921-8
   PubMed Web of Science ®Google Scholar
• Lamberts SW, van Koetsveld PM, Hofland LJ. The effect of clozapine on prolactin secretion at the level of the lactotroph. Life Sci 1990;46(14):1013-19
   PubMed Web of Science ®Google Scholar
• Brown AS, Gewirtz G, Harkavy-Friedman J, Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology 1997;17(5):317-25
   PubMed Web of Science ®Google Scholar
• Henderson DC, Goff DC, Connolly CE, Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 2001;62(8):605-8
   PubMed Web of Science ®Google Scholar
• Markianos M, Hatzimanolis J, Lykouras L. Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur Neuropsychopharmacol 1999;9(6):533-6
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Goode DJ, Schyve PM, Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979;136(12):1550-5
   PubMed Web of Science ®Google Scholar
• Pickar D, Owen RR, Litman RE, Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49(5):345-53
   PubMed Web of Science ®Google Scholar
• Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl) 2000;148(1):3-15
   PubMed Web of Science ®Google Scholar
• de Leon J, Diaz FJ, Josiassen RC, Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. Eur Arch Psychiatry Clin Neurosci 2004;254(5):318-25
   PubMed Web of Science ®Google Scholar
• Bunker MT, Marken PA, Schneiderhan ME, Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. J Child Adolesc Psychopharmacol 1997;7(1):65-9
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The seroquel trial 13 study group. Biol Psychiatry 1997;42(4):233-46
   PubMed Web of Science ®Google Scholar
• Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996;16(2):158-69
   PubMed Web of Science ®Google Scholar
• Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000;30(1):95-105
   PubMed Web of Science ®Google Scholar
• Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112(2-3):285-92
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Arch Gen Psychiatry 1997;54(6):549-57
   PubMed Web of Science ®Google Scholar
• Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res 2004;66(2-3):143-50
   PubMed Web of Science ®Google Scholar
• Byerly MJ, Marcus RN, Tran QV, Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 2009;107(2-3):218-22
   PubMed Web of Science ®Google Scholar
• Casey DE, Carson WH, Saha AR, Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166(4):391-9
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR, Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-71
   PubMed Web of Science ®Google Scholar
• Lee BH, Kim YK. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(4):658-62
   PubMed Web of Science ®Google Scholar
• Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(8):1978-81
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Galluzzo A, Valsecchi P, Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res 2009;110(1-3):80-9
   PubMed Web of Science ®Google Scholar
• Miceli JJ, Wilner KD, Hansen RA, Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol 2000;49(Suppl 1):5S-13S
   PubMedGoogle Scholar
• Marder SR, McQuade RD, Stock E, Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-36
   PubMed Web of Science ®Google Scholar
• Leucht S, Pitschel-Walz G, Engel RR, Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159(2):180-90
   PubMed Web of Science ®Google Scholar
• Clement-Lacroix P, Ormandy C, Lepescheux L, Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinology 1999;140(1):96-105
   PubMed Web of Science ®Google Scholar
• Coss D, Yang L, Kuo CB, Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab 2000;279(6):E1216-25
   PubMed Web of Science ®Google Scholar
• Seriwatanachai D, Thongchote K, Charoenphandhu N, Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 2008;42(3):535-46
   PubMed Web of Science ®Google Scholar
• Ritchie LD, Fung EB, Halloran BP, A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. Am J Clin Nutr 1998;67(4):693-701
   PubMed Web of Science ®Google Scholar
• Seriwatanachai D, Charoenphandhu N, Suthiphongchai T, Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol Int 2008;32(9):1126-35
   PubMed Web of Science ®Google Scholar
• Lotinun S, Limlomwongse L, Sirikulchayanonta V, Bone calcium turnover, formation, and resorption in bromocriptine- and prolactin-treated lactating rats. Endocrine 2003;20(1-2):163-70
   PubMed Web of Science ®Google Scholar
• Puntheeranurak S, Charoenphandhu N, Krishnamra N. Enhanced trabecular-bone calcium deposition in female rats with a high physiological dose of prolactin diminishes after ovariectomy. Can J Physiol Pharmacol 2006;84(10):993-1002
   PubMed Web of Science ®Google Scholar
• Cann CE, Martin M C, Genant HK, Decreased spinal mineral content in amenorrheic women. JAMA 1984;251(5):626-9
   PubMed Web of Science ®Google Scholar
• Schlechte JA, Sherman B, Martin R. Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 1983;56(6):1120-3
   PubMed Web of Science ®Google Scholar
• Torring O, Isberg B, Sjoberg HE, Plasma calcitonin, IGF-I levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment. Acta Endocrinol (Copenh) 1993;128(5):423-7
   PubMedGoogle Scholar
• Di Somma C, Colao A, Di Sarno A, Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998;83(3):807-13
   PubMed Web of Science ®Google Scholar
• O'Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005;25(1):26-31
   PubMed Web of Science ®Google Scholar
• Abraham G, Halbreich U, Friedman RH, Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res 2003;59(1):17-18
   PubMed Web of Science ®Google Scholar
• Halbreich U, Rojansky N, Palter S, Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995;57(5):485-91
   PubMed Web of Science ®Google Scholar
• Jung DU, Conley RR, Kelly DL, Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry 2006;67(9):1391-6
   PubMed Web of Science ®Google Scholar
• Liperoti R, Onder G, Lapane KL, Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry 2007;68(6):929-34
   PubMed Web of Science ®Google Scholar
• Pouwels S, van Staa TP, Egberts AC, Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2009;20(9):1499-506
   PubMed Web of Science ®Google Scholar
• Ray WA, Griffin MR, Schaffner W, Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316(7):363-9
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 2006;17(6):807-16
   PubMed Web of Science ®Google Scholar
• Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. Epidemiol Rev 1997;19(2):244-57
   PubMed Web of Science ®Google Scholar
• Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004;65(12):1607-18, quiz 1590, 1760-1
   PubMed Web of Science ®Google Scholar
• Renn JH, Yang NP, Chueh CM, Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord2009;10:1
   PubMedGoogle Scholar